Segal Scott, Narayanan Ramesh, Dalton James T
1GTx, Inc., Memphis, TN 38163, USA.
Expert Opin Investig Drugs. 2006 Apr;15(4):377-87. doi: 10.1517/13543784.15.4.377.
Selective androgen receptor modulators (SARMS) bind to the androgen receptor and demonstrate anabolic activity in a variety of tissues; however, unlike testosterone and other anabolic steroids, these nonsteroidal agents are able to induce bone and muscle growth, as well as shrinking the prostate. The potential of SARMS is to maximise the positive attributes of steroidal androgens as well as minimising negative effects, thus providing therapeutic opportunities in a variety of diseases, including muscle wasting associated with burns, cancer, end-stage renal disease, osteoporosis, frailty and hypogonadism. This review summarises androgen physiology, the current status of the R&D of SARMS and potential therapeutic indications for this emerging class of drugs.
选择性雄激素受体调节剂（SARMS）与雄激素受体结合，并在多种组织中表现出合成代谢活性；然而，与睾酮和其他合成代谢类固醇不同，这些非甾体药物能够促进骨骼和肌肉生长，同时缩小前列腺体积。SARMS的潜力在于最大化甾体雄激素的积极特性，同时最小化负面影响，从而为多种疾病提供治疗机会，包括与烧伤、癌症、终末期肾病、骨质疏松症、身体虚弱和性腺功能减退相关的肌肉萎缩。本综述总结了雄激素生理学、SARMS的研发现状以及这类新兴药物的潜在治疗适应症。
